Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers
Name
cancers-13-05098.pdf
Size
14.92 MB
Format
Unknown
Checksum (MD5)
77f28bc102b2ff7551a213e45b3c6adc
Author(s)
Mudra, Sarah E.
Sadhukhan, Pritam
Ugurlu, M. Talha
Alam, Shorna
Hoque, Mohammad O.
Date Issued
October 2021
Journal
Cancers
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Cancers 13 (20): 5098 (2021)
Version
Final published version
Abstract
Resistance to cancer therapy remains a significant obstacle in treating patients with various solid malignancies. Exposure to current chemotherapeutics and targeted agents invariably leads to therapy resistance, heralding the need for novel agents. Cancer stem cells (CSCs)—a subpopulation of tumor cells with capacities for self-renewal and multi-lineage differentiation—represent a pool of therapeutically resistant cells. CSCs often share physical and molecular characteristics with the stem cell population of the human body. It remains challenging to selectively target CSCs in therapeutically resistant tumors. The generation of CSCs and induction of therapeutic resistance can be attributed to several deregulated critical growth regulatory signaling pathways such as WNT/β-catenin, Notch, Hippo, and Hedgehog. Beyond growth regulatory pathways, CSCs also change the tumor microenvironment and resist endogenous immune attack. Thus, CSCs can interfere with each stage of carcinogenesis from malignant transformation to the onset of metastasis to tumor recurrence. A thorough review of novel targeted agents to act against CSCs is fundamental for advancing cancer treatment in the setting of both intrinsic and acquired resistance.
MIT Department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.3390/cancers13205098
